Cargando…

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations

BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chih-Jen, Tsai, Ming-Ju, Hung, Jen-Yu, Lee, Mei-Hsuan, Tsai, Ying-Ming, Tsai, Yu-Chen, Hsu, Jui-Feng, Liu, Ta-Chih, Huang, Ming-Shyan, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729426/
https://www.ncbi.nlm.nih.gov/pubmed/29237484
http://dx.doi.org/10.1186/s40360-017-0190-1
_version_ 1783286192868950016
author Yang, Chih-Jen
Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Tsai, Ying-Ming
Tsai, Yu-Chen
Hsu, Jui-Feng
Liu, Ta-Chih
Huang, Ming-Shyan
Chong, Inn-Wen
author_facet Yang, Chih-Jen
Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Tsai, Ying-Ming
Tsai, Yu-Chen
Hsu, Jui-Feng
Liu, Ta-Chih
Huang, Ming-Shyan
Chong, Inn-Wen
author_sort Yang, Chih-Jen
collection PubMed
description BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a dose reduction. No previous study has compared the clinical efficacy and ADRs of different initial doses (40 mg vs. 30 mg daily) of afatinib in lung cancer treatment. METHODS: Patients with stage IV lung adenocarcinoma diagnosed and treated in two Kaohsiung Medical University-affiliated hospitals in Taiwan between May 2014 and August 2016 were identified and followed until December 2016. Demographic characteristics, responses, progression-free survival (PFS), overall survival (OS), and ADRs were recorded. RESULT: A total of 48 patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations who received afatinib as their first-line therapy were enrolled. Patients using 30 mg daily as the initial dose tended to be older and female and have a smaller body size. The patients using 30 mg of afatinib daily as their initial dose had a similar response rate to those receiving 40 mg daily (76% vs. 95%, p = 0.0862) and the same disease control rate (100% vs. 100%, p = 0.1486). The PFS was similar between the patients receiving 30 mg or 40 mg of afatinib daily (median PFS: 469 vs. 443 days, log-rank p = 0.8418). Patients receiving 30 mg daily had a significantly lower incidence of diarrhea than those using 40 mg daily (41% vs. 100%, p < 0.0001). CONCLUSION: An initial afatinib dose of 30 mg daily had similar response and progression-free survival rates as an initial dose of 40 mg daily, but resulted in fewer serious ADRs in this study.
format Online
Article
Text
id pubmed-5729426
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57294262017-12-18 The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations Yang, Chih-Jen Tsai, Ming-Ju Hung, Jen-Yu Lee, Mei-Hsuan Tsai, Ying-Ming Tsai, Yu-Chen Hsu, Jui-Feng Liu, Ta-Chih Huang, Ming-Shyan Chong, Inn-Wen BMC Pharmacol Toxicol Research Article BACKGROUND: Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Compared to cytotoxic chemotherapy, afatinib has been shown to have better efficacy in the treatment of non-small cell lung cancer harboring EGFR mutations. However, 40 mg daily as the initial dose is often accompanied by serious adverse drug reactions (ADRs) and 28 to 53.3% of patients required a dose reduction. No previous study has compared the clinical efficacy and ADRs of different initial doses (40 mg vs. 30 mg daily) of afatinib in lung cancer treatment. METHODS: Patients with stage IV lung adenocarcinoma diagnosed and treated in two Kaohsiung Medical University-affiliated hospitals in Taiwan between May 2014 and August 2016 were identified and followed until December 2016. Demographic characteristics, responses, progression-free survival (PFS), overall survival (OS), and ADRs were recorded. RESULT: A total of 48 patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations who received afatinib as their first-line therapy were enrolled. Patients using 30 mg daily as the initial dose tended to be older and female and have a smaller body size. The patients using 30 mg of afatinib daily as their initial dose had a similar response rate to those receiving 40 mg daily (76% vs. 95%, p = 0.0862) and the same disease control rate (100% vs. 100%, p = 0.1486). The PFS was similar between the patients receiving 30 mg or 40 mg of afatinib daily (median PFS: 469 vs. 443 days, log-rank p = 0.8418). Patients receiving 30 mg daily had a significantly lower incidence of diarrhea than those using 40 mg daily (41% vs. 100%, p < 0.0001). CONCLUSION: An initial afatinib dose of 30 mg daily had similar response and progression-free survival rates as an initial dose of 40 mg daily, but resulted in fewer serious ADRs in this study. BioMed Central 2017-12-13 /pmc/articles/PMC5729426/ /pubmed/29237484 http://dx.doi.org/10.1186/s40360-017-0190-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Yang, Chih-Jen
Tsai, Ming-Ju
Hung, Jen-Yu
Lee, Mei-Hsuan
Tsai, Ying-Ming
Tsai, Yu-Chen
Hsu, Jui-Feng
Liu, Ta-Chih
Huang, Ming-Shyan
Chong, Inn-Wen
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title_full The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title_fullStr The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title_full_unstemmed The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title_short The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
title_sort clinical efficacy of afatinib 30 mg daily as starting dose may not be inferior to afatinib 40 mg daily in patients with stage iv lung adenocarcinoma harboring exon 19 or exon 21 mutations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729426/
https://www.ncbi.nlm.nih.gov/pubmed/29237484
http://dx.doi.org/10.1186/s40360-017-0190-1
work_keys_str_mv AT yangchihjen theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaimingju theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT hungjenyu theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT leemeihsuan theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaiyingming theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaiyuchen theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT hsujuifeng theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT liutachih theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT huangmingshyan theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT chonginnwen theclinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT yangchihjen clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaimingju clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT hungjenyu clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT leemeihsuan clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaiyingming clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT tsaiyuchen clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT hsujuifeng clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT liutachih clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT huangmingshyan clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations
AT chonginnwen clinicalefficacyofafatinib30mgdailyasstartingdosemaynotbeinferiortoafatinib40mgdailyinpatientswithstageivlungadenocarcinomaharboringexon19orexon21mutations